Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for IFTBF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning IFTBF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: IFTBF is a Strong Buy candidate.
IFTBF stock price ended at $5.47 on 木曜日, after rising 14.44%
On the latest trading day Jan 08, 2026, the stock price of IFTBF rose by 14.44%, climbing from $5.47 to $5.47. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $5.47 and a high of $5.47. Alongside this price increase, trading volume also rose by 348 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 852 shares were traded, amounting to a market value of approximately --.